Koido Shigeo, Hara Eiichi, Homma Sadamu, Namiki Yoshihisa, Ohkusa Toshifumi, Gong Jianlin, Tajiri Hisao
Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo 277-8567, Japan. shigeo
Clin Dev Immunol. 2009;2009:657369. doi: 10.1155/2009/657369. Epub 2010 Feb 18.
Dendritic cells (DCs) are potent antigen-presenting cells and play a central role in the initiation and regulation of primary immune responses. Therefore, their use for the active immunotherapy against cancers has been studied with considerable interest. The fusion of DCs with whole tumor cells represents in many ways an ideal approach to deliver, process, and subsequently present a broad array of tumor-associated antigens, including those yet to be unidentified, in the context of DCs-derived costimulatory molecules. DCs/tumor fusion vaccine stimulates potent antitumor immunity in the animal tumor models. In the human studies, T cells stimulated by DC/tumor fusion cells are effective in lysis of tumor cells that are used as the fusion partner. In the clinical trials, clinical and immunological responses were observed in patients with advanced stage of malignant tumors after being vaccinated with DC/tumor fusion cells, although the antitumor effect is not as vigorous as in the animal tumor models. This review summarizes recent advances in concepts and techniques that are providing new impulses to DCs/tumor fusions-based cancer vaccination.
树突状细胞（DCs）是强大的抗原呈递细胞，在初始免疫反应的启动和调节中发挥核心作用。因此，人们对其用于癌症主动免疫治疗进行了大量研究。DCs与完整肿瘤细胞的融合在许多方面代表了一种理想的方法，可在DCs衍生的共刺激分子的背景下递送、加工并随后呈递多种肿瘤相关抗原，包括那些尚未明确的抗原。DCs/肿瘤融合疫苗在动物肿瘤模型中可刺激强大的抗肿瘤免疫力。在人体研究中，由DC/肿瘤融合细胞刺激的T细胞可有效裂解用作融合伙伴的肿瘤细胞。在临床试验中，晚期恶性肿瘤患者接种DC/肿瘤融合细胞后观察到了临床和免疫反应，尽管其抗肿瘤效果不如动物肿瘤模型中那么显著。本综述总结了概念和技术方面的最新进展，这些进展为基于DCs/肿瘤融合的癌症疫苗接种提供了新的动力。
